Browse by author
Lookup NU author(s): Dr Ross Maxwell
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The anti-vascular effects of the tubulin binding agent, disodium combretastatin A-4 3-O-phosphate (CA-4-P), have been investigated in the rat P22 carcinosarcoma by measurements of radiolabelled iodoantipyrine uptake and dynamic contrast-enhanced MRI. The iodoantipyrine estimates of absolute tumour blood flow showed a reduction from 0.35 to 0.04 ml g-1 min-1 6 h after 10 mg kg-1 CA-4-P and to <0.01 ml g-1 min-1 after 100 mg kg-1. Tumour blood flow recovered to control values 24 h after 10 mg kg-1 CA-4-P, but there was no recovery by 24 h after the higher dose. Dynamic contrast-enhanced MR images were obtained at 4.7 T, following injection of 0.1 mmol kg-1 Gd-DTPA and analysed assuming a model arterial input function. A parameter, Ktrans, which is related to blood flow rate and permeability of the tumour vasculature to Gd-DTPA, was calculated from the uptake data. Ktrans showed a reduction from 0.34 to 0.11 min-1 6 h after 10 mg kg-1 CA-4-P and to 0.07 min-1 after 100 mg kg-1. Although the magnitude of changes in Ktrans was smaller than that in tumour blood flow, the time course and dose-dependency patterns were very similar. The apparent extravascular extracellular volume fraction, e, showed a four-fold reduction 6 h after 100 mg kg-1 CA-4-P, possibly associated with vascular shutdown within large regions of the tumour. These results suggest that Ktrans values for Gd-DTPA uptake into tumours could be a useful non-invasive indicator of blood flow changes induced by anti-vascular agents such as combretastatin.
Author(s): Maxwell RJ, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM, Wilson J
Publication type: Article
Publication status: Published
Journal: NMR in Biomedicine
ISSN (print): 0952-3480
ISSN (electronic): 1099-1492
Publisher: John Wiley & Sons Ltd.
Notes: RJM led study. Implementaion of non-invasive magnetic resonance techniques in animals for maximal compatability with invasive animal studies and with magnetic resonance measurements in patients during early phase clinical trials.
Altmetrics provided by Altmetric